← 產業報告目錄

AI in Biotechnology Market by Function (Drug Design & Optimization, Biomarker, SAR; Clinical Trial Design, Data Assessment, RWE, Inventory, Supply Chain, Logistics; Launch, Pricing, Patient Engagement, Adverse Events) and End User - Global Forecast to 2035

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-11-14頁數 596報告編號 HIT9205

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global AI in biotechnology market is projected to reach USD 22,716.5 million by 2035 from USD 4,156.9 million in 2025, at a high CAGR of 18.5% during the forecast period. The market is progressing steadily, driven by the growing adoption of AI for predictive analytics in drug safety and efficacy, the increasing use of AI-powered automation in laboratory processes, and the rising demand for cost-efficient and accelerated research pipelines. Moreover, the expanding availability of large-scale biological datasets, advancements in cloud computing infrastructure, and supportive government initiatives promoting AI in life sciences further propel market growth. The convergence of AI with emerging biotechnologies is enabling faster innovation, improved decision-making, and more personalized healthcare solutions. “The research & development segment of the AI in biotechnology market is the largest segment during the forecast period.” Based on function, the research & development (R&D) segment accounted for the largest share of the AI in biotechnology market and is projected to maintain its lead in the coming years. This dominance is driven by the increasing use of AI to accelerate drug discovery, optimize molecular design, and predict compound efficacy and safety. AI-powered tools enable researchers to analyze large-scale genomic, proteomic, and clinical datasets more efficiently, reducing experimental timelines and costs. Additionally, the integration of machine learning algorithms with high-throughput screening and automated laboratory platforms is enhancing the precision and scalability of R&D processes. As biotech companies strive to bring novel therapeutics to market faster, the adoption of AI in R&D continues to be a key growth driver. “Based on the end user, the pharmaceutical companies segment accounted for the largest share of AI in biotechnology market during the forecast period.” The pharmaceutical companies segment accounted for the largest share of the AI in biotechnology market during the forecast period. This growth is driven by the increasing adoption of AI for accelerating drug discovery, optimizing clinical trial design, and predicting drug efficacy and safety profiles. Pharmaceutical firms are leveraging AI to analyze large-scale biological and clinical datasets, identify novel drug targets, and streamline R&D workflows, reducing time and cost. Additionally, AI-enabled predictive modeling and virtual screening tools help companies make data-driven decisions, enhance success rates, and bring new therapies to market more efficiently. The rising demand for personalized medicine and the pressure to innovate rapidly further reinforce the adoption of AI within the pharmaceutical sector. “Asia Pacific is projected to witness the highest growth rate during the forecast period.” The Asia Pacific region is projected to witness the highest growth rate in the AI in biotechnology market during the forecast period. This rapid expansion is driven by a strong focus on technological advancement and research excellence. Countries across the region are strengthening their innovation ecosystems through enhanced infrastructure, academic-industry partnerships, and cross-border collaborations. The growing emphasis on precision medicine, data-driven healthcare, and sustainable biomanufacturing is also creating new opportunities for market development. Moreover, supportive regulatory frameworks and increasing public-private initiatives position Asia Pacific as a global hub for next-generation biotechnological progress. In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the AI in biotechnology marketplace. The breakdown of primary participants is as mentioned below: • By Company Type - Tier 1: 34%, Tier 2: 46%, and Tier 3: 20% • By Designation - C-Level: 35%, Director Level: 25%, and Others: 40% • By Region - North America: 30%, Europe: 45%, Asia Pacific: 20%, Latin America: 3%, Middle East & Africa: 2% Key Players in the AI in Biotechnology Market The key players operating in the AI in biotechnology market include NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schrödinger, Inc. (US), BenevolentAI (UK), Data4Cure, Inc. (US), Qiagen (Germany), Insilico Medicine (US), DNAnexus, Inc. (US), Tempus (US), SOPHiA GENETIC (Switzerland), Predictive Oncology (US), Deep Genomics (Canada), NuMedii, Inc. (US), XtalPi Inc. (China), Iktos (France), BPGbio, Inc. (US), Eurofins Discovery (US), VeriSIM Life (US), Lifebit (UK), Verge Genomics (US), Logica (US), American Chemical Society (US), and Aganitha AI Inc. (India). Research Coverage The report analyzes the AI in biotechnology market and aims to estimate the market size and future growth potential of various market segments, based on offering, function, deployment mode, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies. Reasons to Buy the Report This report will benefit established firms as well as new entrants and smaller firms in gauging the market pulse, which in turn will help them capture a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market. This report provides insights into the following:  Analysis of key drivers (growing cross-industry collaborations and partnerships, growing need to reduce time and cost of drug discovery and development, rising adoption of AI in precision medicine, improving computing power and declining hardware cost), restraints (high implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies, data privacy risks and compliance challenges for AI in biotechnology), opportunities (integrating AI and big data in precision medicine for biotechnology advancement, surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations, innovation across healthcare, agriculture, and environmental science for global growth) challenges (data quality and interpretability issues that hinder AI integration and trustworthiness, AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges) influencing the growth of the AI in biotechnology market  Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in biotechnology market  Market Development: Comprehensive information on the lucrative emerging markets, offering, function, deployment mode, end user, and region  Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in biotechnology market  Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in biotechnology market, like NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schrödinger Inc. (US), and BenevolentAI (UK)
目錄 Table of Contents
1 INTRODUCTION 53 1.1 STUDY OBJECTIVES 53 1.2 MARKET DEFINITION 53 1.3 STUDY SCOPE 54 1.3.1 MARKETS COVERED & REGIONAL SCOPE 54 1.3.2 INCLUSIONS & EXCLUSIONS 55 1.3.3 YEARS CONSIDERED 56 1.3.4 CURRENCY CONSIDERED 57 1.4 RESEARCH LIMITATIONS 57 1.5 STAKEHOLDERS 58 2 RESEARCH METHODOLOGY 59 2.1 RESEARCH DATA 59 2.1.1 SECONDARY DATA 60 2.1.1.1 Key data from secondary sources 61 2.1.2 PRIMARY DATA 61 2.1.2.1 Key data from primary sources 63 2.1.2.2 Insights from primary experts 64 2.2 MARKET SIZE ESTIMATION 65 2.3 DATA TRIANGULATION 69 2.4 MARKET SHARE ESTIMATION 69 2.5 RESEARCH ASSUMPTIONS 70 2.6 RESEARCH LIMITATIONS 70 2.6.1 METHODOLOGY-RELATED LIMITATIONS 70 2.6.2 SCOPE-RELATED LIMITATIONS 70 2.7 RISK ASSESSMENT 71 3 EXECUTIVE SUMMARY 72 4 PREMIUM INSIGHTS 76 4.1 AI IN BIOTECHNOLOGY MARKET OVERVIEW 76 4.2 AI IN BIOTECHNOLOGY MARKET, BY REGION 77 4.3 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING AND COUNTRY 78 4.4 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHIC SNAPSHOT 79 4.5 AI IN BIOTECHNOLOGY MARKET: DEVELOPED VS. EMERGING ECONOMIES 79   5 MARKET OVERVIEW 80 5.1 INTRODUCTION 80 5.2 MARKET DYNAMICS 80 5.2.1 DRIVERS 82 5.2.1.1 Growing cross-industry collaborations and partnerships 82 5.2.1.2 Increasing need to reduce time and cost of drug discovery & development 83 5.2.1.3 Rising adoption of AI in precision medicine 84 5.2.1.4 Increasing investments in semiconductor chipsets 85 5.2.2 RESTRAINTS 85 5.2.2.1 High implementation costs 85 5.2.2.2 Data privacy risks and compliance challenges 85 5.2.3 OPPORTUNITIES 86 5.2.3.1 Rise of advanced analytics and predictive modeling 86 5.2.3.2 Surge in biotechnology investments 87 5.2.3.3 Innovations across healthcare, agriculture, and environmental science 87 5.2.4 CHALLENGES 88 5.2.4.1 Data quality and interpretability issues 88 5.2.4.2 Shortage of qualified experts and evolving regulatory challenges 88 5.3 UNMET NEEDS AND WHITE SPACES 89 5.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 90 5.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 91 6 INDUSTRY TRENDS 92 6.1 EVOLUTION OF AI IN BIOTECHNOLOGY 92 6.2 PORTER’S FIVE FORCES ANALYSIS 94 6.2.1 BARGAINING POWER OF SUPPLIERS 95 6.2.2 BARGAINING POWER OF BUYERS 95 6.2.3 THREAT OF SUBSTITUTES 95 6.2.4 THREAT OF NEW ENTRANTS 95 6.2.5 INTENSITY OF COMPETITIVE RIVALRY 95 6.3 MACROECONOMICS INDICATORS 95 6.3.1 INTRODUCTION 95 6.3.2 GDP TRENDS AND FORECAST 96 6.3.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 96 6.4 VALUE CHAIN ANALYSIS 96 6.5 ECOSYSTEM ANALYSIS 97 6.6 PRICING ANALYSIS 100 6.6.1 INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY OFFERING, BY KEY PLAYERS (2024) 100 6.6.2 INDICATIVE PRICING OF AI IN BIOTECHNOLOGY, BY REGION 101 6.7 KEY CONFERENCES AND EVENTS, 2025–2026 101 6.8 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 102 6.9 INVESTMENT AND FUNDING SCENARIO 103 6.10 CASE STUDY ANALYSIS 103 6.10.1 CASE STUDY 1: RAPID TRAINING OF PROTEIN MODELS USING NVIDIA DGX CLOUD 103 6.10.2 CASE STUDY 2: IMPROVED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION 104 6.10.3 CASE STUDY 3: ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS 104 6.11 IMPACT OF 2025 US TARIFF ON AI IN BIOTECHNOLOGY MARKET 105 6.11.1 INTRODUCTION 105 6.11.2 KEY TARIFF RATES 105 6.11.3 PRICE IMPACT ANALYSIS 106 6.11.4 IMPACT ON COUNTRIES/REGIONS 106 6.11.4.1 North America 106 6.11.4.2 Europe 107 6.11.4.3 Asia Pacific 107 6.11.5 IMPACT ON END-USE INDUSTRIES 107 6.11.5.1 Pharmaceutical companies 107 6.11.5.2 Biotechnology companies 107 6.11.5.3 Research institutes and labs 108 6.11.5.4 Healthcare providers 108 6.11.5.5 Contract Research Organizations (CROs) 108 7 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS 109 7.1 KEY EMERGING TECHNOLOGIES 109 7.1.1 NATURAL LANGUAGE PROCESSING (NLP) 109 7.1.2 PREDICTIVE ANALYTICS 109 7.2 COMPLEMENTARY TECHNOLOGIES 109 7.2.1 CLOUD COMPUTING 109 7.2.2 BIG DATA ANALYTICS 109 7.3 TECHNOLOGY/PRODUCT ROADMAP 110 7.4 PATENT ANALYSIS 111 7.4.1 PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY 111 7.4.2 JURISDICTION AND TOP APPLICANT ANALYSIS 111 7.5 FUTURE APPLICATIONS 116 7.5.1 AI-ENABLED PRECISION DISCOVERY AND MULTI-OMICS INTEGRATION 116 7.5.2 GENERATIVE BIOLOGY AND AUTOMATED DESIGN OF MOLECULES, PROTEINS, AND GENETIC SYSTEMS 117   7.6 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET 117 7.6.1 INTRODUCTION 117 7.6.2 TOP USE CASES AND MARKET POTENTIAL 118 7.6.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 119 7.6.3.1 Drug discovery and development market 119 7.6.3.2 Genomics and bioinformatics market 120 7.6.3.3 Medical imaging & diagnostics market 120 7.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN AI IN BIOTECHNOLOGY MARKET 120 7.6.4.1 User readiness 120 7.6.4.1.1 Pharmaceutical companies 120 7.6.4.1.2 Biotechnology companies 120 7.6.4.2 Impact assessment 121 7.6.4.2.1 User A: Pharmaceutical companies 121 7.6.4.2.1.1 Implementation 121 7.6.4.2.1.2 Impact 121 7.6.4.2.2 User B: Biotechnology companies 121 7.6.4.2.2.1 Implementation 121 7.6.4.2.2.2 Impact 122 7.6.5 CASE STUDY ON AI/GENERATIVE AI IMPLEMENTATION 122 7.6.5.1 Case Study 1: Enhanced operations and revenue using AI-driven real-world data analytics 122 7.6.5.2 Case study 2: Advance AI-powered target discovery with proprietary AI platform 123 8 REGULATORY LANDSCAPE 124 8.1 REGIONAL REGULATIONS AND COMPLIANCE 124 8.1.1 NORTH AMERICA 124 8.1.2 EUROPE 125 8.1.3 ASIA PACIFIC 126 8.1.4 LATIN AMERICA 127 8.1.5 MIDDLE EAST & AFRICA 127 8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 128 8.3 INDUSTRY STANDARDS 130 9 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 131 9.1 DECISION-MAKING PROCESS 131 9.2 INFLUENCE OF STAKEHOLDERS AND BUYING CRITERIA 131 9.2.1 BUYING CRITERIA 132 9.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 133 9.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 133 9.5 END-USER EXPECTATIONS 134 10 AI IN BIOTECHNOLOGY MARKET, BY OFFERING 135 10.1 INTRODUCTION 136 10.2 END-TO-END SOLUTIONS 137 10.2.1 GROWING USE OF ADVANCED ALGORITHMS FOR BETTER PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH 137 10.3 NICHE SOLUTIONS 138 10.3.1 ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION 138 10.4 TECHNOLOGIES 139 10.4.1 ADOPTION OF ADVANCED TECHNOLOGIES FOR DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH 139 10.5 SERVICES 141 10.5.1 CONSULTING SERVICES 142 10.5.1.1 Increasing efficiency of research processes and cost savings to boost adoption 142 10.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT 143 10.5.2.1 Increasing precision and efficiency in IT support services to boost demand 143 10.5.3 TRAINING & EDUCATION SERVICES 144 10.5.3.1 Need for skilled talent for better training & education services to drive market 144 10.5.4 POST-SALES & MAINTENANCE SERVICES 145 10.5.4.1 Complexity of AI systems and need for improvement in AI algorithms to boost market 145 11 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 147 11.1 INTRODUCTION 148 11.2 RESEARCH & DEVELOPMENT 149 11.2.1 DRUG DISCOVERY 151 11.2.1.1 Molecular design & optimization 153 11.2.1.1.1 Increased efficiency in drug discovery with molecular design & optimization to drive market 153 11.2.1.2 Biomarker discovery 154 11.2.1.2.1 Ability to analyze large data sets with AI-enabled biomarker discovery to boost demand 154 11.2.1.3 Structure-activity relationship (SAR) modeling 155 11.2.1.3.1 Improved data analysis, predictive modeling, and compound optimization for drug candidates with SAR to fuel growth 155 11.2.2 CLINICAL DEVELOPMENT 156 11.2.2.1 Trial design 158 11.2.2.1.1 Ability of AI to improve trial design through simulations and patient stratification to favor market 158 11.2.2.2 Site selection 159 11.2.2.2.1 Optimized process of selecting clinical trial sites to fuel growth 159 11.2.2.3 Recruitment 160 11.2.2.3.1 Enhanced process of selecting and enrolling participants for clinical trials to drive demand 160 11.2.2.4 Clinical data assessment 161 11.2.2.4.1 Ability of clinical data assessment for efficient and accurate of data interpretation to propel market 161 11.2.2.5 Predictive toxicity & risk monitoring 162 11.2.2.5.1 Ability of data integration and predictive modeling to create comprehensive risk profiles for drug candidates 162 11.2.2.6 Monitoring & drug adherence 163 11.2.2.6.1 Enhanced patient compliance with monitoring and drug adherence to drive market 163 11.2.2.7 Real-world evidence (RWE) analysis 164 11.2.2.7.1 Enhanced safety monitoring and economic evaluation with RWE analysis to propel growth 164 11.3 REGULATORY COMPLIANCE 165 11.3.1 ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH 165 11.4 MANUFACTURING & SUPPLY CHAIN 166 11.4.1 SUPPLY CHAIN PLANNING 168 11.4.1.1 Increasing demand for real-time data analytics to accelerate market growth 168 11.4.2 INVENTORY MANAGEMENT 169 11.4.2.1 Automating stock tracking and replenishment with advanced analytics to fuel market growth 169 11.4.3 LOGISTICS OPTIMIZATION 170 11.4.3.1 Ability of AI for increased collaboration and transparency in biotechnology logistics to aid growth 170 11.4.4 DEMAND FORECASTING 171 11.4.4.1 Ability to integrate data for a reliable demand forecast to fuel market growth 171 11.4.5 PREDICTIVE MAINTENANCE 172 11.4.5.1 Boosting equipment reliability with AI-powered predictive maintenance to drive demand 172 11.4.6 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS 173 11.5 LAUNCH & COMMERCIAL 174 11.5.1 LAUNCH COORDINATION 176 11.5.1.1 Increasing product launch success rates through predictive analytics to boost adoption 176 11.5.2 PATIENT ENGAGEMENT 177 11.5.2.1 Real-time patient feedback for better health outcomes to support growth 177 11.5.3 MARKETING OPERATIONS 178 11.5.3.1 Enhanced marketing performance with AI to boost market growth 178 11.5.4 PREDICTIVE PRICING 179 11.5.4.1 Ability of AI to enhance pricing accuracy to drive adoption 179 11.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT 180 11.6.1 MEDICATION ADHERENCE 182 11.6.1.1 Growing demand for personalized treatment plans to drive market 182 11.6.2 ADVERSE EVENT REPORTING 184 11.6.2.1 Faster post-market surveillance and enhanced drug safety to drive demand 184 11.6.3 PATIENT MONITORING 185 11.6.3.1 Rise of remote healthcare solutions to boost market demand 185 11.6.4 COMPLIANCE MONITORING 186 11.6.4.1 Increasing complexity of regulatory requirements to drive adoption 186 11.6.5 PATIENT SUPPORT PROGRAMS 187 11.6.5.1 Growing interest in patient-centered care to support market growth 187 11.7 CORPORATE 188 11.7.1 RISK MANAGEMENT 189 11.7.1.1 Rising expenditure for drug development to support growth 189 11.7.2 COMPLIANCE MONITORING 190 11.7.2.1 Strict guidelines for complex regulatory landscapes to aid market growth 190 11.7.3 SALES FORCE OPTIMIZATION 191 11.7.3.1 Need for data-driven decision-making to boost adoption of sales force optimization 191 11.7.4 OTHER CORPORATE FUNCTIONS 192 12 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 194 12.1 INTRODUCTION 195 12.2 CLOUD-BASED SOLUTIONS 195 12.2.1 PUBLIC CLOUD 197 12.2.1.1 Need to reduce dependency on expensive on-premises infrastructure to boost demand 197 12.2.2 PRIVATE CLOUD 198 12.2.2.1 Need for enhanced security and data protection to propel market growth 198 12.2.3 MULTI-CLOUD 199 12.2.3.1 Enhanced flexibility and cost optimization to support market growth 199 12.2.4 HYBRID CLOUD 201 12.2.4.1 Cost efficiency and flexibility of hybrid cloud models to fuel market growth 201 12.3 ON-PREMISES SOLUTIONS 202 12.3.1 BETTER DATA SECURITY, PRIVACY, AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH 202   13 AI IN BIOTECHNOLOGY MARKET, BY END USER 204 13.1 INTRODUCTION 205 13.2 PHARMACEUTICAL COMPANIES 206 13.2.1 INNOVATION AND EFFICIENCY WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION 206 13.3 BIOTECHNOLOGY COMPANIES 207 13.3.1 ABILITY OF AI-DRIVEN INNOVATIONS FOR BETTER PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT MARKET GROWTH 207 13.4 RESEARCH INSTITUTES & LABS 208 13.4.1 STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS 208 13.5 HEALTHCARE PROVIDERS 210 13.5.1 IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION 210 13.6 CONTRACT RESEARCH ORGANIZATIONS 211 13.6.1 ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH 211 14 AI IN BIOTECHNOLOGY MARKET, BY REGION 213 14.1 INTRODUCTION 214 14.2 NORTH AMERICA 215 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 227 14.2.2 US 227 14.2.2.1 US to dominate North American AI in biotechnology market during study period 227 14.2.3 CANADA 238 14.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market 238 14.3 EUROPE 249 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 261 14.3.2 GERMANY 261 14.3.2.1 Increased funding in startups to drive uptake of AI in biotechnology 261 14.3.3 UK 272 14.3.3.1 Increasing investments and government fund allocations to drive market 272 14.3.4 FRANCE 283 14.3.4.1 Government initiatives in France to support market growth 283 14.3.5 ITALY 294 14.3.5.1 Growing investments to create opportunities for market growth 294 14.3.6 SPAIN 305 14.3.6.1 Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market 305 14.3.7 REST OF EUROPE 316   14.4 ASIA PACIFIC 327 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 340 14.4.2 JAPAN 340 14.4.2.1 Accelerating AI-driven drug discovery and biotechnology innovation to drive Japanese market 340 14.4.3 CHINA 351 14.4.3.1 Rising foreign investments in biotechnology and biopharmaceuticals to propel market growth 351 14.4.4 INDIA 362 14.4.4.1 Increasing number of startups and growing support from government to propel market growth 362 14.4.5 SOUTH KOREA 373 14.4.5.1 Significant advances in AI integration for R&D to fuel growth 373 14.4.6 AUSTRALIA 384 14.4.6.1 Accelerating AI adoption in Australia’s biotech sector to augment market growth 384 14.4.7 REST OF ASIA PACIFIC 395 14.5 LATIN AMERICA 406 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 418 14.5.2 BRAZIL 418 14.5.2.1 Funding of biotech companies to drive Brazilian market growth 418 14.5.3 MEXICO 429 14.5.3.1 Investment inflows and strengthening AI-related education to spur market growth 429 14.5.4 REST OF LATIN AMERICA 440 14.6 MIDDLE EAST & AFRICA 451 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 463 14.6.2 GCC COUNTRIES 463 14.6.2.1 Increase in healthcare investments to support market growth 463 14.6.3 REST OF MIDDLE EAST & AFRICA 475 15 COMPETITIVE LANDSCAPE 487 15.1 INTRODUCTION 487 15.2 KEY PLAYER STRATEGY/RIGHT TO WIN 487 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN BIOTECHNOLOGY MARKET 487 15.3 REVENUE ANALYSIS, 2020–2024 490 15.4 MARKET SHARE ANALYSIS, 2024 490 15.4.1 RANKING OF KEY MARKET PLAYERS 493 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 493 15.5.1 STARS 493 15.5.2 EMERGING LEADERS 493 15.5.3 PERVASIVE PLAYERS 494 15.5.4 PARTICIPANTS 494 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 495 15.5.5.1 Company footprint 495 15.5.5.2 Region footprint 496 15.5.5.3 Component footprint 497 15.5.5.4 Function footprint 498 15.5.5.5 End-user footprint 499 15.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 500 15.6.1 PROGRESSIVE COMPANIES 500 15.6.2 RESPONSIVE COMPANIES 500 15.6.3 DYNAMIC COMPANIES 500 15.6.4 STARTING BLOCKS 500 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 502 15.6.5.1 Detailed list of key startups/SMEs 502 15.6.5.2 Competitive benchmarking of key startups/SME players 503 15.7 COMPANY VALUATION & FINANCIAL METRICS 504 15.7.1 FINANCIAL METRICS 504 15.7.2 COMPANY VALUATION 504 15.8 BRAND/PRODUCT COMPARISON 505 15.9 COMPETITIVE SCENARIO 506 15.9.1 PRODUCT LAUNCHES & UPGRADES 506 15.9.2 DEALS 507 15.9.3 EXPANSIONS 509 16 COMPANY PROFILES 510 16.1 KEY PLAYERS 510 16.1.1 NVIDIA CORPORATION 510 16.1.1.1 Business overview 510 16.1.1.2 Products offered 511 16.1.1.3 Recent developments 512 16.1.1.3.1 Product launches 512 16.1.1.3.2 Deals 512 16.1.1.4 MnM view 515 16.1.1.4.1 Right to win 515 16.1.1.4.2 Strategic choices 515 16.1.1.4.3 Weaknesses & competitive threats 515 16.1.2 ILLUMINA, INC. 516 16.1.2.1 Business overview 516 16.1.2.2 Products offered 517 16.1.2.3 Recent developments 518 16.1.2.3.1 Product launches 518 16.1.2.3.2 Deals 519   16.1.2.4 MnM view 521 16.1.2.4.1 Right to win 521 16.1.2.4.2 Strategic choices 521 16.1.2.4.3 Weaknesses & competitive threats 521 16.1.3 RECURSION 522 16.1.3.1 Business overview 522 16.1.3.2 Products offered 523 16.1.3.3 Recent developments 523 16.1.3.3.1 Product launches 523 16.1.3.3.2 Deals 523 16.1.3.3.3 Expansions 525 16.1.3.3.4 Other developments 526 16.1.3.4 MnM view 526 16.1.3.4.1 Right to win 526 16.1.3.4.2 Strategic choices 526 16.1.3.4.3 Weaknesses & competitive threats 526 16.1.4 SCHRÖDINGER, INC. 527 16.1.4.1 Business overview 527 16.1.4.2 Products offered 528 16.1.4.3 Recent developments 529 16.1.4.3.1 Product upgrades 529 16.1.4.3.2 Deals 529 16.1.4.3.3 Other developments 531 16.1.4.4 MnM view 531 16.1.4.4.1 Right to win 531 16.1.4.4.2 Strategic choices 532 16.1.4.4.3 Weaknesses & competitive threats 532 16.1.5 BENEVOLENTAI 533 16.1.5.1 Business overview 533 16.1.5.2 Products offered 534 16.1.5.3 Recent developments 534 16.1.5.3.1 Deals 534 16.1.5.3.2 Other developments 535 16.1.5.4 MnM view 536 16.1.5.4.1 Right to win 536 16.1.5.4.2 Strategic choices 536 16.1.5.4.3 Weaknesses & competitive threats 536 16.1.6 DATA4CURE, INC. 537 16.1.6.1 Business overview 537 16.1.6.2 Products offered 537 16.1.6.3 Recent developments 538 16.1.6.3.1 Deals 538 16.1.7 QIAGEN 539 16.1.7.1 Business overview 539 16.1.7.2 Products offered 540 16.1.7.3 Recent developments 541 16.1.7.3.1 Product launches and enhancements 541 16.1.7.3.2 Deals 541 16.1.8 INSILICO MEDICINE 543 16.1.8.1 Business overview 543 16.1.8.2 Products offered 543 16.1.8.3 Recent developments 544 16.1.8.3.1 Product launches, approvals, and enhancements 544 16.1.8.3.2 Deals 545 16.1.8.3.3 Other developments 546 16.1.9 DNANEXUS, INC. 547 16.1.9.1 Business overview 547 16.1.9.2 Products offered 547 16.1.9.3 Recent developments 548 16.1.9.3.1 Deals 548 16.1.9.3.2 Other developments 550 16.1.10 TEMPUS 551 16.1.10.1 Business overview 551 16.1.10.2 Products offered 551 16.1.10.3 Recent developments 552 16.1.10.3.1 Product approvals 552 16.1.10.3.2 Deals 552 16.1.10.3.3 Other developments 554 16.1.11 SOPHIA GENETICS 555 16.1.11.1 Business overview 555 16.1.11.2 Products offered 556 16.1.11.3 Recent developments 557 16.1.11.3.1 Product launches 557 16.1.11.3.2 Deals 557 16.1.11.3.3 Other developments 559 16.1.12 PREDICTIVE ONCOLOGY 560 16.1.12.1 Business overview 560 16.1.12.2 Products offered 561 16.1.12.3 Recent developments 561 16.1.12.3.1 Product launches 561 16.1.12.3.2 Deals 561 16.1.12.3.3 Expansions 562   16.1.13 DEEP GENOMICS 563 16.1.13.1 Business overview 563 16.1.13.2 Products offered 563 16.1.13.3 Recent developments 564 16.1.13.3.1 Product launches 564 16.1.14 NUMEDII, INC. 565 16.1.14.1 Business overview 565 16.1.14.2 Products offered 565 16.1.15 XTALPI INC. 566 16.1.15.1 Business overview 566 16.1.15.2 Products offered 567 16.1.15.3 Recent developments 568 16.1.15.3.1 Deals 568 16.1.16 IKTOS 570 16.1.16.1 Business overview 570 16.1.16.2 Products offered 570 16.1.16.3 Recent developments 571 16.1.16.3.1 Product launches 571 16.1.16.3.2 Deals 571 16.1.16.3.3 Other developments 572 16.1.17 BPGBIO, INC. 573 16.1.17.1 Business overview 573 16.1.17.2 Products offered 573 16.1.17.3 Recent developments 574 16.1.17.3.1 Product launches 574 16.1.17.3.2 Deals 574 16.1.17.3.3 Other developments 575 16.1.18 EUROFINS DISCOVERY 576 16.1.18.1 Business overview 576 16.1.18.2 Products offered 577 16.1.18.3 Recent developments 577 16.1.18.3.1 Product launches 577 16.1.18.3.2 Deals 578 16.1.18.3.3 Expansions 579 16.2 OTHER PLAYERS 580 16.2.1 VERISIM LIFE 580 16.2.2 LIFEBIT BIOTECH INC. 580 16.2.3 VALO HEALTH 581 16.2.4 VERGE GENOMICS 581 16.2.5 LOGICA 582 16.2.6 AMERICAN CHEMICAL SOCIETY 583 16.2.7 AGANITHA AI INC. 584 17 APPENDIX 585 17.1 DISCUSSION GUIDE 585 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 592 17.3 CUSTOMIZATION OPTIONS 594 17.4 RELATED REPORTS 594 17.5 AUTHOR DETAILS 595
圖表清單 List of Tables & Figures
TABLE 1 AI IN BIOTECHNOLOGY MARKET: INCLUSIONS & EXCLUSIONS 55 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 57 TABLE 3 AI IN BIOTECHNOLOGY MARKET: RESEARCH ASSUMPTIONS 70 TABLE 4 AI IN BIOTECHNOLOGY MARKET: RISK ASSESSMENT 71 TABLE 5 AI IN BIOTECHNOLOGY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 81 TABLE 6 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN AI IN BIOTECHNOLOGY MARKET, 2022−2025 82 TABLE 7 TABLE AI IN BIOTECHNOLOGY MARKET: UNMET NEEDS 89 TABLE 8 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 94 TABLE 9 FIGURE 5 AI IN BIOTECHNOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 99 TABLE 10 TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY OFFERINGS, BY KEY PLAYER, 2024 (USD) 100 TABLE 11 TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY REGION (2024) 101 TABLE 12 AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 101 TABLE 13 US ADJUSTED RECIPROCAL TARIFF RATES 105 TABLE 14 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES, 2015–2025 112 TABLE 15 TABLE AI IN BIOTECHNOLOGY MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2022–2025 114 TABLE 16 REGULATORY SCENARIO OF NORTH AMERICA 124 TABLE 17 REGULATORY SCENARIO OF EUROPE 125 TABLE 18 REGULATORY SCENARIO OF ASIA PACIFIC 126 TABLE 19 REGULATORY SCENARIO OF LATIN AMERICA 127 TABLE 20 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 127 TABLE 21 TABLE NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 128 TABLE 22 TABLE EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 128 TABLE 23 TABLE ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 129 TABLE 24 TABLE REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 129 TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%) 132 TABLE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS 132 TABLE 27 UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET 133 TABLE 28 TABLE END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET 134 TABLE 29 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 136 TABLE 30 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 136 TABLE 31 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2023–2029 (USD MILLION) 137 TABLE 32 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2030–2035 (USD MILLION) 138 TABLE 33 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION, 2023–2029 (USD MILLION) 139 TABLE 34 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION, 2030–2035 (USD MILLION) 139 TABLE 35 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION, 2023–2029 (USD MILLION) 140 TABLE 36 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION, 2030–2035 (USD MILLION) 140 TABLE 37 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION, 2023–2029 (USD MILLION) 141 TABLE 38 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION, 2030–2035 (USD MILLION) 141 TABLE 39 CONSULTING SERVICES MARKET, BY REGION, 2023–2029 (USD MILLION) 142 TABLE 40 CONSULTING SERVICES MARKET, BY REGION, 2030–2035 (USD MILLION) 142 TABLE 41 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2023–2029 (USD MILLION) 143 TABLE 42 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2030–2035 (USD MILLION) 143 TABLE 43 TRAINING AND EDUCATION SERVICES MARKET, BY REGION, 2023–2029 (USD MILLION) 144 TABLE 44 TRAINING AND EDUCATION SERVICES MARKET, BY REGION, 2030–2035 (USD MILLION) 144 TABLE 45 POST-SALES AND MAINTENANCE SERVICES MARKET, BY REGION, 2023–2029 (USD MILLION) 145 TABLE 46 AI IN BIOTECHNOLOGY MARKET FOR POST-SALES AND MAINTENANCE SERVICES, BY REGION, 2030–2035 (USD MILLION) 146 TABLE 47 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 148 TABLE 48 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 148 TABLE 49 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 149 TABLE 50 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 150 TABLE 51 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2023–2029 (USD MILLION) 150 TABLE 52 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2030–2035 (USD MILLION) 150 TABLE 53 EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY 151 TABLE 54 DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 151 TABLE 55 DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 152 TABLE 56 DRUG DISCOVERY MARKET, BY REGION, 2023–2029 (USD MILLION) 152 TABLE 57 DRUG DISCOVERY MARKET, BY REGION, 2030–2035 (USD MILLION) 152 TABLE 58 MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION) 153 TABLE 59 MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION) 153 TABLE 60 BIOMARKER DISCOVERY MARKET, BY REGION, 2023–2029 (USD MILLION) 154 TABLE 61 BIOMARKER DISCOVERY MARKET, BY REGION, 2030–2035 (USD MILLION) 154 TABLE 62 STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2023–2029 (USD MILLION) 155 TABLE 63 STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2030–2035 (USD MILLION) 155 TABLE 64 CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 156 TABLE 65 CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 157 TABLE 66 CLINICAL DEVELOPMENT MARKET, BY REGION, 2023–2029 (USD MILLION) 157 TABLE 67 CLINICAL DEVELOPMENT MARKET, BY REGION, 2030–2035 (USD MILLION) 158 TABLE 68 TRIAL DESIGN MARKET, BY REGION, 2023–2029 (USD MILLION) 158 TABLE 69 TRIAL DESIGN MARKET, BY REGION, 2030–2035 (USD MILLION) 159 TABLE 70 SITE SELECTION MARKET, BY REGION, 2023–2029 (USD MILLION) 159 TABLE 71 SITE SELECTION MARKET, BY REGION, 2030–2035 (USD MILLION) 160 TABLE 72 RECRUITMENT MARKET, BY REGION, 2023–2029 (USD MILLION) 160 TABLE 73 RECRUITMENT MARKET, BY REGION, 2030–2035 (USD MILLION) 161 TABLE 74 CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2023–2029 (USD MILLION) 161 TABLE 75 CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2030–2035 (USD MILLION) 162 TABLE 76 PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION) 162 TABLE 77 PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION) 163 TABLE 78 MONITORING & DRUG ADHERENCE MARKET, BY REGION, 2023–2029 (USD MILLION) 163 TABLE 79 MONITORING & DRUG ADHERENCE MARKET, BY REGION, 2030–2035 (USD MILLION) 164 TABLE 80 REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION, 2023–2029 (USD MILLION) 164 TABLE 81 REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION, 2030–2035 (USD MILLION) 165 TABLE 82 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2023–2029 (USD MILLION) 166 TABLE 83 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2030–2035 (USD MILLION) 166 TABLE 84 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 167 TABLE 85 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 167 TABLE 86 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY REGION, 2023–2029 (USD MILLION) 168 TABLE 87 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY REGION, 2030–2035 (USD MILLION) 168 TABLE 88 SUPPLY CHAIN PLANNING MARKET, BY REGION, 2023–2029 (USD MILLION) 169 TABLE 89 SUPPLY CHAIN PLANNING MARKET, BY REGION, 2030–2035 (USD MILLION) 169 TABLE 90 INVENTORY MANAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION) 170 TABLE 91 INVENTORY MANAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION) 170 TABLE 92 LOGISTICS OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION) 171 TABLE 93 LOGISTICS OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION) 171 TABLE 94 DEMAND FORECASTING MARKET, BY REGION, 2023–2029 (USD MILLION) 172 TABLE 95 DEMAND FORECASTING MARKET, BY REGION, 2030–2035 (USD MILLION) 172 TABLE 96 PREDICTIVE MAINTENANCE MARKET, BY REGION, 2023–2029 (USD MILLION) 173 TABLE 97 PREDICTIVE MAINTENANCE MARKET, BY REGION, 2030–2035 (USD MILLION) 173 TABLE 98 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2023–2029 (USD MILLION) 174 TABLE 99 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2030–2035 (USD MILLION) 174 TABLE 100 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 175 TABLE 101 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 175 TABLE 102 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION, 2023–2029 (USD MILLION) 176 TABLE 103 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION, 2030–2035 (USD MILLION) 176 TABLE 104 LAUNCH COORDINATION MARKET, BY REGION, 2023–2029 (USD MILLION) 177 TABLE 105 LAUNCH COORDINATION MARKET, BY REGION, 2030–2035 (USD MILLION) 177 TABLE 106 PATIENT ENGAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION) 178 TABLE 107 PATIENT ENGAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION) 178 TABLE 108 MARKETING OPERATIONS MARKET, BY REGION, 2023–2029 (USD MILLION) 179 TABLE 109 MARKETING OPERATIONS MARKET, BY REGION, 2030–2035 (USD MILLION) 179 TABLE 110 PREDICTIVE PRICING MARKET, BY REGION, 2023–2029 (USD MILLION) 180 TABLE 111 PREDICTIVE PRICING MARKET, BY REGION, 2030–2035 (USD MILLION) 180 TABLE 112 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 181 TABLE 113 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 181 TABLE 114 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2023–2029 (USD MILLION) 182 TABLE 115 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2030–2035 (USD MILLION) 182 TABLE 116 MEDICATION ADHERENCE MARKET, BY REGION, 2023–2029 (USD MILLION) 183 TABLE 117 MEDICATION ADHERENCE MARKET, BY REGION, 2030–2035 (USD MILLION) 183 TABLE 118 ADVERSE EVENT REPORTING MARKET, BY REGION, 2023–2029 (USD MILLION) 184 TABLE 119 ADVERSE EVENT REPORTING MARKET, BY REGION, 2030–2035 (USD MILLION) 184 TABLE 120 PATIENT MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION) 185 TABLE 121 PATIENT MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION) 185 TABLE 122 COMPLIANCE MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION) 186 TABLE 123 COMPLIANCE MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION) 186 TABLE 124 PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2023–2029 (USD MILLION) 187 TABLE 125 PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2030–2035 (USD MILLION) 187 TABLE 126 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 188 TABLE 127 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 188 TABLE 128 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION, 2023–2029 (USD MILLION) 189 TABLE 129 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION, 2030–2035 (USD MILLION) 189 TABLE 130 RISK MANAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION) 190 TABLE 131 RISK MANAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION) 190 TABLE 132 COMPLIANCE MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION) 191 TABLE 133 COMPLIANCE MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION) 191 TABLE 134 SALES FORCE OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION) 192 TABLE 135 SALES FORCE OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION) 192 TABLE 136 OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2023–2029 (USD MILLION) 193 TABLE 137 OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2030–2035 (USD MILLION) 193 TABLE 138 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 195 TABLE 139 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 195 TABLE 140 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 196 TABLE 141 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 196 TABLE 142 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2023–2029 (USD MILLION) 196 TABLE 143 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2030–2035 (USD MILLION) 197 TABLE 144 PUBLIC CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION) 198 TABLE 145 PUBLIC CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION) 198 TABLE 146 PRIVATE CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION) 199 TABLE 147 PRIVATE CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION) 199 TABLE 148 MULTI CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION) 200 TABLE 149 MULTI CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION) 200 TABLE 150 HYBRID CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION) 201 TABLE 151 HYBRID CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION) 201 TABLE 152 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2023–2029 (USD MILLION) 202 TABLE 153 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2030–2035 (USD MILLION) 203 TABLE 154 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 205 TABLE 155 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 205 TABLE 156 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023–2029 (USD MILLION) 206 TABLE 157 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2030–2035 (USD MILLION) 207 TABLE 158 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2029 (USD MILLION) 208 TABLE 159 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2030–2035 (USD MILLION) 208 TABLE 160 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2023–2029 (USD MILLION) 209 TABLE 161 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2030–2035 (USD MILLION) 209 TABLE 162 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2023–2029 (USD MILLION) 210 TABLE 163 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2030–2035 (USD MILLION) 211 TABLE 164 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2029 (USD MILLION) 212 TABLE 165 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2030–2035 (USD MILLION) 212 TABLE 166 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2023–2029 (USD MILLION) 214 TABLE 167 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2030–2035 (USD MILLION) 214 TABLE 168 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2023–2029 (USD MILLION) 216 TABLE 169 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2030–2035 (USD MILLION) 216 TABLE 170 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 216 TABLE 171 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 217 TABLE 172 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 217 TABLE 173 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 218 TABLE 174 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 218 TABLE 175 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 219 TABLE 176 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 219 TABLE 177 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 219 TABLE 178 NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 220 TABLE 179 NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 220 TABLE 180 NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 221 TABLE 181 NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 221 TABLE 182 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 222 TABLE 183 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 222 TABLE 184 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 223 TABLE 185 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 223 TABLE 186 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 223 TABLE 187 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 224 TABLE 188 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 224 TABLE 189 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 225 TABLE 190 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 225 TABLE 191 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 225 TABLE 192 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 226 TABLE 193 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 226 TABLE 194 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 226 TABLE 195 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 227 TABLE 196 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 228 TABLE 197 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 228 TABLE 198 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 228 TABLE 199 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 229 TABLE 200 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 229 TABLE 201 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 230 TABLE 202 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 230 TABLE 203 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 230 TABLE 204 US: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 231 TABLE 205 US: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 231 TABLE 206 US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 231 TABLE 207 US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 232 TABLE 208 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 232 TABLE 209 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 233 TABLE 210 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 233 TABLE 211 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 234 TABLE 212 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 234 TABLE 213 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 235 TABLE 214 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 235 TABLE 215 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 236 TABLE 216 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 236 TABLE 217 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 236 TABLE 218 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 237 TABLE 219 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 237 TABLE 220 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 237 TABLE 221 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 238 TABLE 222 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 238 TABLE 223 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 239 TABLE 224 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 239 TABLE 225 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 239 TABLE 226 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 240 TABLE 227 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 240 TABLE 228 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 241 TABLE 229 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 241 TABLE 230 CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 241 TABLE 231 CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 242 TABLE 232 CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 242 TABLE 233 CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 243 TABLE 234 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 243 TABLE 235 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 244 TABLE 236 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 244 TABLE 237 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 245 TABLE 238 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 245 TABLE 239 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 246 TABLE 240 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 246 TABLE 241 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 247 TABLE 242 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 247 TABLE 243 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 247 TABLE 244 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 248 TABLE 245 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 248 TABLE 246 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 248 TABLE 247 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 249 TABLE 248 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2023–2029 (USD MILLION) 250 TABLE 249 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2030–2035 (USD MILLION) 250 TABLE 250 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 251 TABLE 251 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 251 TABLE 252 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 251 TABLE 253 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 252 TABLE 254 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 252 TABLE 255 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 253 TABLE 256 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 253 TABLE 257 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 253 TABLE 258 EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 254 TABLE 259 EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 254 TABLE 260 EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 254 TABLE 261 EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 255 TABLE 262 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 255 TABLE 263 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 256 TABLE 264 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 256 TABLE 265 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 257 TABLE 266 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 257 TABLE 267 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 258 TABLE 268 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 258 TABLE 269 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 259 TABLE 270 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 259 TABLE 271 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 259 TABLE 272 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 260 TABLE 273 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 260 TABLE 274 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 260 TABLE 275 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 261 TABLE 276 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 262 TABLE 277 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 262 TABLE 278 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 262 TABLE 279 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 263 TABLE 280 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 263 TABLE 281 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 264 TABLE 282 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 264 TABLE 283 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 264 TABLE 284 GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 265 TABLE 285 GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 265 TABLE 286 GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 265 TABLE 287 GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 266 TABLE 288 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 266 TABLE 289 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 267 TABLE 290 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 267 TABLE 291 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 268 TABLE 292 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 268 TABLE 293 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 269 TABLE 294 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 269 TABLE 295 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 270 TABLE 296 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 270 TABLE 297 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 270 TABLE 298 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 271 TABLE 299 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 271 TABLE 300 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 271 TABLE 301 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 272 TABLE 302 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 272 TABLE 303 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 273 TABLE 304 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 273 TABLE 305 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 273 TABLE 306 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 274 TABLE 307 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 274 TABLE 308 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 275 TABLE 309 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 275 TABLE 310 UK: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 275 TABLE 311 UK: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 276 TABLE 312 UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 276 TABLE 313 UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 277 TABLE 314 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 277 TABLE 315 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 278 TABLE 316 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 278 TABLE 317 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 279 TABLE 318 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 279 TABLE 319 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 280 TABLE 320 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 280 TABLE 321 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 281 TABLE 322 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 281 TABLE 323 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 281 TABLE 324 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 282 TABLE 325 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 282 TABLE 326 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 282 TABLE 327 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 283 TABLE 328 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 284 TABLE 329 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 284 TABLE 330 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 284 TABLE 331 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 285 TABLE 332 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 285 TABLE 333 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 286 TABLE 334 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 286 TABLE 335 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 286 TABLE 336 FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 287 TABLE 337 FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 287 TABLE 338 FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 287 TABLE 339 FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 288 TABLE 340 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 288 TABLE 341 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 289 TABLE 342 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 289 TABLE 343 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 290 TABLE 344 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 290 TABLE 345 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 291 TABLE 346 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 291 TABLE 347 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 292 TABLE 348 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 292 TABLE 349 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 292 TABLE 350 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 293 TABLE 351 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 293 TABLE 352 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 293 TABLE 353 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 294 TABLE 354 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 295 TABLE 355 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 295 TABLE 356 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 295 TABLE 357 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 296 TABLE 358 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 296 TABLE 359 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 297 TABLE 360 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 297 TABLE 361 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 297 TABLE 362 ITALY: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 298 TABLE 363 ITALY: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 298 TABLE 364 ITALY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 298 TABLE 365 ITALY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 299 TABLE 366 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 299 TABLE 367 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 300 TABLE 368 ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 300 TABLE 369 ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 301 TABLE 370 ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 301 TABLE 371 ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 302 TABLE 372 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 302 TABLE 373 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 303 TABLE 374 ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 303 TABLE 375 ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 303 TABLE 376 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 304 TABLE 377 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 304 TABLE 378 ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 304 TABLE 379 ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 305 TABLE 380 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 305 TABLE 381 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 306 TABLE 382 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 306 TABLE 383 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 306 TABLE 384 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 307 TABLE 385 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 307 TABLE 386 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 308 TABLE 387 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 308 TABLE 388 SPAIN: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 308 TABLE 389 SPAIN: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 309 TABLE 390 SPAIN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 309 TABLE 391 SPAIN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 310 TABLE 392 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 310 TABLE 393 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 311 TABLE 394 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 311 TABLE 395 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 312 TABLE 396 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 312 TABLE 397 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 313 TABLE 398 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 313 TABLE 399 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 314 TABLE 400 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 314 TABLE 401 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 314 TABLE 402 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 315 TABLE 403 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 315 TABLE 404 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 315 TABLE 405 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 316 TABLE 406 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 317 TABLE 407 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 317 TABLE 408 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 317 TABLE 409 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 318 TABLE 410 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 318 TABLE 411 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 319 TABLE 412 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 319 TABLE 413 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 319 TABLE 414 REST OF EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 320 TABLE 415 REST OF EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 320 TABLE 416 REST OF EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 320 TABLE 417 REST OF EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 321 TABLE 418 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 321 TABLE 419 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 322 TABLE 420 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 322 TABLE 421 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 323 TABLE 422 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 323 TABLE 423 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 324 TABLE 424 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 324 TABLE 425 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 325 TABLE 426 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 325 TABLE 427 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 325 TABLE 428 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 326 TABLE 429 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 326 TABLE 430 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 326 TABLE 431 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 327 TABLE 432 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2023–2029 (USD MILLION) 328 TABLE 433 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2030–2035 (USD MILLION) 329 TABLE 434 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 329 TABLE 435 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 329 TABLE 436 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 330 TABLE 437 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 330 TABLE 438 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 331 TABLE 439 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 331 TABLE 440 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 332 TABLE 441 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 332 TABLE 442 ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 332 TABLE 443 ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 333 TABLE 444 ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 333 TABLE 445 ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 334 TABLE 446 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 334 TABLE 447 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 335 TABLE 448 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 335 TABLE 449 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 336 TABLE 450 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 336 TABLE 451 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 337 TABLE 452 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 337 TABLE 453 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 338 TABLE 454 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 338 TABLE 455 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 338 TABLE 456 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 339 TABLE 457 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 339 TABLE 458 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 339 TABLE 459 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 340 TABLE 460 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 341 TABLE 461 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 341 TABLE 462 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 341 TABLE 463 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 342 TABLE 464 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 342 TABLE 465 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 343 TABLE 466 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 343 TABLE 467 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 343 TABLE 468 JAPAN: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 344 TABLE 469 JAPAN: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 344 TABLE 470 JAPAN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 344 TABLE 471 JAPAN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 345 TABLE 472 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 345 TABLE 473 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 346 TABLE 474 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 346 TABLE 475 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 347 TABLE 476 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 347 TABLE 477 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 348 TABLE 478 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 348 TABLE 479 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 349 TABLE 480 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 349 TABLE 481 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 349 TABLE 482 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 350 TABLE 483 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 350 TABLE 484 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 350 TABLE 485 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 351 TABLE 486 CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 352 TABLE 487 CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 352 TABLE 488 CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 352 TABLE 489 CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 353 TABLE 490 CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 353 TABLE 491 CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 354 TABLE 492 CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 354 TABLE 493 CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 354 TABLE 494 CHINA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 355 TABLE 495 CHINA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 355 TABLE 496 CHINA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 355 TABLE 497 CHINA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 356 TABLE 498 CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 356 TABLE 499 CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 357 TABLE 500 CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 357 TABLE 501 CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 358 TABLE 502 CHINA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 358 TABLE 503 CHINA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 359 TABLE 504 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 359 TABLE 505 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 360 TABLE 506 CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 360 TABLE 507 CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 360 TABLE 508 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 361 TABLE 509 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 361 TABLE 510 CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 361 TABLE 511 CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 362 TABLE 512 INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 362 TABLE 513 INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 363 TABLE 514 INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 363 TABLE 515 INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 363 TABLE 516 INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 364 TABLE 517 INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 364 TABLE 518 INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 365 TABLE 519 INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 365 TABLE 520 INDIA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 365 TABLE 521 INDIA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 366 TABLE 522 INDIA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 366 TABLE 523 INDIA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 367 TABLE 524 INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 367 TABLE 525 INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 368 TABLE 526 INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 368 TABLE 527 INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 369 TABLE 528 INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 369 TABLE 529 INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 370 TABLE 530 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 370 TABLE 531 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 371 TABLE 532 INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 371 TABLE 533 INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 371 TABLE 534 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 372 TABLE 535 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 372 TABLE 536 INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 372 TABLE 537 INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 373 TABLE 538 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 374 TABLE 539 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 374 TABLE 540 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 374 TABLE 541 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 375 TABLE 542 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 375 TABLE 543 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 376 TABLE 544 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 376 TABLE 545 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 376 TABLE 546 SOUTH KOREA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 377 TABLE 547 SOUTH KOREA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 377 TABLE 548 SOUTH KOREA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 377 TABLE 549 SOUTH KOREA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 378 TABLE 550 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 378 TABLE 551 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 379 TABLE 552 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 379 TABLE 553 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 380 TABLE 554 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 380 TABLE 555 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 381 TABLE 556 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 381 TABLE 557 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 382 TABLE 558 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 382 TABLE 559 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 382 TABLE 560 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 383 TABLE 561 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 383 TABLE 562 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 383 TABLE 563 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 384 TABLE 564 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 384 TABLE 565 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 385 TABLE 566 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 385 TABLE 567 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 385 TABLE 568 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 386 TABLE 569 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 386 TABLE 570 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 387 TABLE 571 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 387 TABLE 572 AUSTRALIA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 387 TABLE 573 AUSTRALIA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 388 TABLE 574 AUSTRALIA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 388 TABLE 575 AUSTRALIA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 389 TABLE 576 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 389 TABLE 577 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 390 TABLE 578 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 390 TABLE 579 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 391 TABLE 580 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 391 TABLE 581 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 392 TABLE 582 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 392 TABLE 583 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 393 TABLE 584 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 393 TABLE 585 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 393 TABLE 586 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 394 TABLE 587 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 394 TABLE 588 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 394 TABLE 589 AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 395 TABLE 590 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 396 TABLE 591 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 396 TABLE 592 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 396 TABLE 593 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 397 TABLE 594 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 397 TABLE 595 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 398 TABLE 596 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 398 TABLE 597 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 398 TABLE 598 REST OF ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 399 TABLE 599 REST OF ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 399 TABLE 600 REST OF ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 399 TABLE 601 REST OF ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 400 TABLE 602 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 400 TABLE 603 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 401 TABLE 604 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 401 TABLE 605 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 402 TABLE 606 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 402 TABLE 607 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 403 TABLE 608 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 403 TABLE 609 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 404 TABLE 610 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 404 TABLE 611 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 404 TABLE 612 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 405 TABLE 613 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 405 TABLE 614 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 405 TABLE 615 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 406 TABLE 616 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2023–2029 (USD MILLION) 406 TABLE 617 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2030–2035 (USD MILLION) 407 TABLE 618 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 407 TABLE 619 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 407 TABLE 620 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 408 TABLE 621 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 408 TABLE 622 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 409 TABLE 623 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 409 TABLE 624 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 410 TABLE 625 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 410 TABLE 626 LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 410 TABLE 627 LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 411 TABLE 628 LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 411 TABLE 629 LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 412 TABLE 630 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 412 TABLE 631 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 413 TABLE 632 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 413 TABLE 633 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 414 TABLE 634 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 414 TABLE 635 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 415 TABLE 636 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 415 TABLE 637 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 416 TABLE 638 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 416 TABLE 639 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 416 TABLE 640 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 417 TABLE 641 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 417 TABLE 642 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 417 TABLE 643 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 418 TABLE 644 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 419 TABLE 645 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 419 TABLE 646 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 419 TABLE 647 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 420 TABLE 648 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 420 TABLE 649 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 421 TABLE 650 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 421 TABLE 651 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 421 TABLE 652 BRAZIL: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 422 TABLE 653 BRAZIL: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 422 TABLE 654 BRAZIL: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 422 TABLE 655 BRAZIL: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 423 TABLE 656 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 423 TABLE 657 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 424 TABLE 658 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 424 TABLE 659 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 425 TABLE 660 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 425 TABLE 661 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 426 TABLE 662 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 426 TABLE 663 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 427 TABLE 664 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 427 TABLE 665 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 427 TABLE 666 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 428 TABLE 667 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 428 TABLE 668 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 428 TABLE 669 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 429 TABLE 670 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 429 TABLE 671 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 430 TABLE 672 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 430 TABLE 673 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 430 TABLE 674 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 431 TABLE 675 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 431 TABLE 676 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 432 TABLE 677 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 432 TABLE 678 MEXICO: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 432 TABLE 679 MEXICO: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 433 TABLE 680 MEXICO: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 433 TABLE 681 MEXICO: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 434 TABLE 682 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 434 TABLE 683 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 435 TABLE 684 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 435 TABLE 685 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 436 TABLE 686 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 436 TABLE 687 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 437 TABLE 688 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 437 TABLE 689 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 438 TABLE 690 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 438 TABLE 691 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 438 TABLE 692 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 439 TABLE 693 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 439 TABLE 694 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 439 TABLE 695 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 440 TABLE 696 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 440 TABLE 697 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 441 TABLE 698 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 441 TABLE 699 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 442 TABLE 700 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 442 TABLE 701 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 443 TABLE 702 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 443 TABLE 703 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 443 TABLE 704 REST OF LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 444 TABLE 705 REST OF LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 444 TABLE 706 REST OF LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 445 TABLE 707 REST OF LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 445 TABLE 708 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 446 TABLE 709 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 446 TABLE 710 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 447 TABLE 711 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 447 TABLE 712 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 447 TABLE 713 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 448 TABLE 714 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 448 TABLE 715 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 449 TABLE 716 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 449 TABLE 717 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 449 TABLE 718 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 450 TABLE 719 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 450 TABLE 720 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 450 TABLE 721 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 451 TABLE 722 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY REGION, 2023–2029 (USD MILLION) 452 TABLE 723 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY REGION, 2030–2035 (USD MILLION) 452 TABLE 724 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 452 TABLE 725 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 453 TABLE 726 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 453 TABLE 727 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 454 TABLE 728 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 454 TABLE 729 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 455 TABLE 730 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 455 TABLE 731 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 455 TABLE 732 MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 456 TABLE 733 MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 456 TABLE 734 MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 457 TABLE 735 MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 457 TABLE 736 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 458 TABLE 737 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 458 TABLE 738 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 459 TABLE 739 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 459 TABLE 740 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 459 TABLE 741 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 460 TABLE 742 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 460 TABLE 743 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 461 TABLE 744 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 461 TABLE 745 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 461 TABLE 746 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 462 TABLE 747 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 462 TABLE 748 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 462 TABLE 749 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 463 TABLE 750 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 465 TABLE 751 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 465 TABLE 752 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 465 TABLE 753 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 466 TABLE 754 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 466 TABLE 755 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 467 TABLE 756 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 467 TABLE 757 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 467 TABLE 758 GCC COUNTRIES: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 468 TABLE 759 GCC COUNTRIES: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 468 TABLE 760 GCC COUNTRIES: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 468 TABLE 761 GCC COUNTRIES: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 469 TABLE 762 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 469 TABLE 763 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 470 TABLE 764 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 470 TABLE 765 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 471 TABLE 766 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 471 TABLE 767 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 472 TABLE 768 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 472 TABLE 769 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 473 TABLE 770 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 473 TABLE 771 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 473 TABLE 772 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 474 TABLE 773 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 474 TABLE 774 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 474 TABLE 775 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 475 TABLE 776 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION) 476 TABLE 777 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION) 476 TABLE 778 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION) 476 TABLE 779 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION) 477 TABLE 780 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION) 477 TABLE 781 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION) 478 TABLE 782 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION) 478 TABLE 783 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION) 478 TABLE 784 REST OF MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION) 479 TABLE 785 REST OF MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION) 479 TABLE 786 REST OF MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION) 480 TABLE 787 REST OF MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION) 480 TABLE 788 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION) 481 TABLE 789 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION) 481 TABLE 790 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION) 482 TABLE 791 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION) 482 TABLE 792 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION) 482 TABLE 793 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION) 483 TABLE 794 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION) 483 TABLE 795 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION) 484 TABLE 796 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION) 484 TABLE 797 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION) 484 TABLE 798 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION) 485 TABLE 799 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION) 485 TABLE 800 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION) 485 TABLE 801 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION) 486 TABLE 802 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, JANUARY 2022–NOVEMBER 2025 487 TABLE 803 AI IN BIOTECHNOLOGY MARKET: DEGREE OF COMPETITION 491 TABLE 804 AI IN BIOTECHNOLOGY: REGION FOOTPRINT 496 TABLE 805 AI IN BIOTECHNOLOGY MARKET: COMPONENT FOOTPRINT 497 TABLE 806 AI IN BIOTECHNOLOGY MARKET: FUNCTION FOOTPRINT 498 TABLE 807 AI IN BIOTECHNOLOGY MARKET: END-USER FOOTPRINT 499 TABLE 808 AI IN BIOTECHNOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 502 TABLE 809 AI IN BIOTECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY OFFERING, FUNCTION, END USER, AND REGION 503 TABLE 810 AI IN BIOTECHNOLOGY MARKET: PRODUCT LAUNCHES & UPGRADES, JANUARY 2022–NOVEMBER 2025 506 TABLE 811 AI IN BIOTECHNOLOGY MARKET: DEALS, JANUARY 2022–NOVEMBER 2025 507 TABLE 812 AI IN BIOTECHNOLOGY MARKET: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 509 TABLE 813 NVIDIA CORPORATION: COMPANY OVERVIEW 510 TABLE 814 NVIDIA CORPORATION: PRODUCTS OFFERED 511 TABLE 815 NVIDIA CORPORATION: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025 512 TABLE 816 NVIDIA CORPORATION: DEALS, JANUARY 2022−NOVEMBER 2025 512 TABLE 817 ILLUMINA, INC.: COMPANY OVERVIEW 516 TABLE 818 ILLUMINA, INC.: PRODUCTS OFFERED 517 TABLE 819 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025 518 TABLE 820 ILLUMINA, INC.: DEALS, JANUARY 2022−NOVEMBER 2025 519 TABLE 821 RECURSION: COMPANY OVERVIEW 522 TABLE 822 RECURSION: PRODUCTS OFFERED 523 TABLE 823 RECURSION: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025 523 TABLE 824 RECURSION: DEALS, JANUARY 2022−NOVEMBER 2025 523 TABLE 825 RECURSION: EXPANSIONS, JANUARY 2022−NOVEMBER 2025 525 TABLE 826 RECURSION: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025 526 TABLE 827 SCHRÖDINGER, INC.: COMPANY OVERVIEW 527 TABLE 828 SCHRÖDINGER, INC.: PRODUCTS OFFERED 528 TABLE 829 SCHRÖDINGER, INC.: PRODUCT UPGRADES, JANUARY 2022−NOVEMBER 2025 529 TABLE 830 SCHRÖDINGER, INC.: DEALS, JANUARY 2022−NOVEMBER 2025 529 TABLE 831 SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025 531 TABLE 832 BENEVOLENTAI: COMPANY OVERVIEW 533 TABLE 833 BENEVOLENTAI: PRODUCTS OFFERED 534 TABLE 834 BENEVOLENTAI: DEALS, JANUARY 2022−NOVEMBER 2025 534 TABLE 835 BENEVOLENTAI: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025 535 TABLE 836 DATA4CURE, INC.: COMPANY OVERVIEW 537 TABLE 837 DATA4CURE, INC.: PRODUCTS OFFERED 537 TABLE 838 DATA4CURE, INC.: DEALS, JANUARY 2022–NOVEMBER 2025 538 TABLE 839 QIAGEN: COMPANY OVERVIEW 539 TABLE 840 QIAGEN: PRODUCTS OFFERED 540 TABLE 841 QIAGEN: PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2022−NOVEMBER 2025 541 TABLE 842 QIAGEN: DEALS, JANUARY 2022−NOVEMBER 2025 541 TABLE 843 INSILICO MEDICINE: COMPANY OVERVIEW 543 TABLE 844 INSILICO MEDICINE: PRODUCTS OFFERED 543 TABLE 845 INSILICO MEDICINE: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2022–NOVEMBER 2025 544 TABLE 846 INSILICO MEDICINE: DEALS, JANUARY 2022–NOVEMBER 2025 545 TABLE 847 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025 546 TABLE 848 DNANEXUS, INC.: COMPANY OVERVIEW 547 TABLE 849 DNANEXUS, INC.: PRODUCTS OFFERED 547 TABLE 850 DNANEXUS, INC.: DEALS, JANUARY 2022−NOVEMBER 2025 548 TABLE 851 DNANEXUS, INC.: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025 550 TABLE 852 TEMPUS: COMPANY OVERVIEW 551 TABLE 853 TEMPUS: PRODUCTS OFFERED 551 TABLE 854 TEMPUS: PRODUCT APPROVALS, JANUARY 2022–NOVEMBER 2025 552 TABLE 855 TEMPUS: DEALS, JANUARY 2022−NOVEMBER 2025 552 TABLE 856 TEMPUS: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025 554 TABLE 857 SOPHIA GENETICS: COMPANY OVERVIEW 555 TABLE 858 SOPHIA GENETICS: PRODUCTS OFFERED 556 TABLE 859 SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025 557 TABLE 860 SOPHIA GENETICS: DEALS, JANUARY 2022−NOVEMBER 2025 557 TABLE 861 SOPHIA GENETICS: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025 559 TABLE 862 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW 560 TABLE 863 PREDICTIVE ONCOLOGY: PRODUCTS OFFERED 561 TABLE 864 PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025 561 TABLE 865 PREDICTIVE ONCOLOGY: DEALS, JANUARY 2022−NOVEMBER 2025 561 TABLE 866 PREDICTIVE ONCOLOGY: EXPANSIONS, JANUARY 2022−NOVEMBER 2025 562 TABLE 867 DEEP GENOMICS: COMPANY OVERVIEW 563 TABLE 868 DEEP GENOMICS: PRODUCTS OFFERED 563 TABLE 869 DEEP GENOMICS: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025 564 TABLE 870 NUMEDII, INC.: COMPANY OVERVIEW 565 TABLE 871 NUMEDII, INC.: PRODUCTS OFFERED 565 TABLE 872 XTALPI INC.: COMPANY OVERVIEW 566 TABLE 873 XTALPI INC.: PRODUCTS OFFERED 567 TABLE 874 XTALPI INC.: DEALS, JANUARY 2022−NOVEMBER 2025 568 TABLE 875 IKTOS: COMPANY OVERVIEW 570 TABLE 876 IKTOS: PRODUCTS OFFERED 570 TABLE 877 IKTOS: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025 571 TABLE 878 IKTOS: DEALS, JANUARY 2022−NOVEMBER 2025 571 TABLE 879 IKTOS: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025 572 TABLE 880 BPGBIO, INC.: COMPANY OVERVIEW 573 TABLE 881 BPGBIO, INC.: PRODUCTS OFFERED 573 TABLE 882 BPGBIO, INC.: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025 574 TABLE 883 BPGBIO, INC.: DEALS, JANUARY 2022−NOVEMBER 2025 574 TABLE 884 BPGBIO, INC.: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025 575 TABLE 885 EUROFINS DISCOVERY: COMPANY OVERVIEW 576 TABLE 886 EUROFINS DISCOVERY: PRODUCTS OFFERED 577 TABLE 887 EUROFINS DISCOVERY: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025 577 TABLE 888 EUROFINS DISCOVERY: DEALS, JANUARY 2022−NOVEMBER 2025 578 TABLE 889 EUROFINS DISCOVERY: EXPANSIONS, JANUARY 2022−NOVEMBER 2025 579 TABLE 890 VERISIM LIFE: COMPANY OVERVIEW 580 TABLE 891 LIFEBIT BIOTECH INC.: COMPANY OVERVIEW 580 TABLE 892 VALO HEALTH: COMPANY OVERVIEW 581 TABLE 893 VERGE GENOMICS: COMPANY OVERVIEW 581 TABLE 894 LOGICA: COMPANY OVERVIEW 582 TABLE 895 AMERICAN CHEMICAL SOCIETY: COMPANY OVERVIEW 583 TABLE 896 AGANITHA AI INC.: COMPANY OVERVIEW 584 FIGURE 1 AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE 54 FIGURE 2 AI IN BIOTECHNOLOGY MARKET: YEARS CONSIDERED 56 FIGURE 3 RESEARCH DESIGN 59 FIGURE 4 PRIMARY SOURCES 62 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY COMPANY, DESIGNATION, AND REGION 64 FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 65 FIGURE 7 TOP-DOWN APPROACH 66 FIGURE 8 AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS 67 FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 68 FIGURE 10 DATA TRIANGULATION 69 FIGURE 11 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2025 VS. 2035 (USD MILLION) 72 FIGURE 12 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2025 VS. 2035 (USD MILLION) 73 FIGURE 13 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2025 VS. 2035 (USD MILLION) 73 FIGURE 14 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION) 74 FIGURE 15 AI IN BIOTECHNOLOGY MARKET: REGIONAL SNAPSHOT 75 FIGURE 16 FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT FUNDING TO DRIVE MARKET 76 FIGURE 17 NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET DURING STUDY PERIOD 77 FIGURE 18 END-TO-END SOLUTIONS AND US COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024 78 FIGURE 19 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 79 FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES FROM 2025 TO 2035 79 FIGURE 21 AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 80 FIGURE 22 EVOLUTION OF AI IN BIOTECHNOLOGY MARKET 93 FIGURE 23 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 94 FIGURE 24 AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS 96 FIGURE 25 AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS 98 FIGURE 26 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 102 FIGURE 27 AI IN BIOTECHNOLOGY MARKET: INVESTMENT AND FUNDING SCENARIO 103 FIGURE 28 AI IN BIOTECHNOLOGY MARKET: PATENT PUBLICATION TRENDS, 2015–2025 111 FIGURE 29 JURISDICTION AND TOP APPLICANT ANALYSIS, 2015–2025 111 FIGURE 30 AI IN BIOTECHNOLOGY MARKET: PATENT ANALYSIS, JANUARY 2015–JANUARY 2025 113 FIGURE 31 MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS 118 FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS 131 FIGURE 33 KEY BUYING CRITERIA FOR TOP THREE END USERS 132 FIGURE 34 NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS, 2019–2023 149 FIGURE 35 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT 215 FIGURE 36 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT 328 FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2020–2024 (USD BILLION) 490 FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2024) 491 FIGURE 39 RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2024) 493 FIGURE 40 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 494 FIGURE 41 AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT 495 FIGURE 42 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2024 501 FIGURE 43 EV/EBITDA OF KEY VENDORS 504 FIGURE 44 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF AI IN BIOTECHNOLOGY SOLUTION VENDORS 504 FIGURE 45 AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 505 FIGURE 46 NVIDIA CORPORATION: COMPANY SNAPSHOT 511 FIGURE 47 ILLUMINA, INC.: COMPANY SNAPSHOT 517 FIGURE 48 RECURSION: COMPANY SNAPSHOT 522 FIGURE 49 SCHRÖDINGER, INC.: COMPANY SNAPSHOT 528 FIGURE 50 BENEVOLENTAI: COMPANY SNAPSHOT 533 FIGURE 51 QIAGEN: COMPANY SNAPSHOT 540 FIGURE 52 SOPHIA GENETICS: COMPANY SNAPSHOT 556 FIGURE 53 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT 560 FIGURE 54 XTALPI INC.: COMPANY SNAPSHOT 567 FIGURE 55 EUROFINS DISCOVERY: COMPANY SNAPSHOT 576

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們